 This study found that the regulation on the reimbursement for anti osteoporosis medication, AOMs, decreased the prescribing rate of AOMs immediately after implementation but had no lasting effect. The study also revealed that the policy regulation was associated with an increasing trend of osteoporotic fracture-related medical expenditures, especially among those very old population. This article was authored by Chen Yu-wang, Xiao Huai-Fu, Chi-Chi-Yan-Hung, and others.